Theravance Biopharma (TBPH) is a US-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of $875M, trading at
6.88 on the NASDAQ. This SniperIQ fundamentals page covers Theravance Biopharma's valuation (P/E 7.5x, P/B 3.0x), profitability (net margin 104.3%), revenue (
07M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Market Cap$875M
P/E (TTM)7.5x
Net Margin104.3%
Revenue (FY25)
07M
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is Theravance Biopharma's market cap?
Theravance Biopharma (TBPH) has a market capitalization of approximately $875M, trading at
6.88 on the NASDAQ. Market cap moves with the live share price.
What is Theravance Biopharma's P/E ratio?
Theravance Biopharma's trailing twelve-month P/E ratio is 7.5x, with a price-to-book (P/B) of 3.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Theravance Biopharma?
Theravance Biopharma runs a net profit margin of 104.3%, a gross margin of 80.4%, and an operating margin of 0.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Theravance Biopharma generate?
Theravance Biopharma reported revenue of
07M for fiscal year 2025, with net income of
06M and earnings per share (EPS) of 2.1. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Theravance Biopharma pay a dividend?
Theravance Biopharma does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Theravance Biopharma financially healthy?
Theravance Biopharma carries a debt-to-equity ratio of 0.25x and a current ratio of 13.14x, with a market beta of 0.17. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Theravance Biopharma a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Theravance Biopharma (TBPH) the key facts are: market cap $875M, P/E 7.5x, revenue
07M, 52-week range 10.822-21.03. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Theravance Biopharma's full fundamentals live
Get Theravance Biopharma's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.